SCHEMBL4126579

SCHEMBL4126579

O=C(O)NCCc1cc(S(=O)(=O)c2ccccn2)n(-c2ccccc2Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 2/20 0.41
SLC16A1 P53985 2/20 0.41
RIPK1 Q13546 1/20 0.39
THRB P10828 2/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 2/20 0.38
PKM P14618 2/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 1/20 0.37
SLC12A2 P55011 1/20 0.37
SLC12A5 Q9H2X9 1/20 0.37
POLB P06746 2/20 0.36
CNR1 P21554 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119656 0.87 P2RX7 (0.39) SLC16A3SLC16A1RIPK1KDM4ESMN1; SMN2
SCHEMBL4118804 0.86 LMNA (0.36) SLC16A3SLC16A1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4125774 0.86 SMN1; SMN2 (0.36) SLC16A3SLC16A1SMN1; SMN2ALDH1A1PKM
SCHEMBL4135079 0.85 SLC16A3 (0.37) SLC16A3SLC16A1RIPK1KDM4ESMN1; SMN2
SCHEMBL4126274 0.83 GAA (0.40) SLC16A3SLC16A1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4126103 0.83 ALDH1A1 (0.42) KDM4ESMN1; SMN2ALDH1A1RAB9ACNR1
SCHEMBL4125307 0.83 NFE2L2 (0.38) SLC16A3SLC16A1SMN1; SMN2ALDH1A1POLB
SCHEMBL4135868 0.83 NAMPT (0.39) SLC16A3SLC16A1SMN1; SMN2ALDH1A1PKM
SCHEMBL4135836 0.82 HTT (0.37) SMN1; SMN2ALDH1A1PKMHTTRAB9A
SCHEMBL4135506 0.82 SLC16A3 (0.37) SLC16A3SLC16A1SMN1; SMN2ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 SLC16A3 2809/4885SLC16A1 2925/4885RIPK1 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.